Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PROLACTIN”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,585 records · Page 88Linked to original sources
PubMed1982

Failure of dopamine and bromocriptine to affect prolactin release and cell growth in the dopamine receptor-deficient 235-1 clone.

The 235-1 clone was recently derived from the 7315a transplantable pituitary tumor and continues to secrete rat prolactin. The cells have a prominent Golgi apparatus which can be stained immunocytochemically for prolactin, but there were no 600-900 nm granules which are characteristic of normal mammotrophs. In a perfused cell-column apparatus, prolactin release from the clone was unchanged by dopaminergic agonists, thyrotropin-releasing hormone and estradiol but stimulated by dibutyryl cyclic AMP. Cellular cyclic AMP content was also not changed by dopamine but was dramatically enhanced by prostaglandin E1, indicating that at least one hormone-adenylate cyclase coupling mechanism was functional. In radioligand binding studies using the dopamine antagonist [3H]spiperone, no evidence of a dopamine receptor was obtained. The [3H]spiperone binding present was not stereoselective, and exceedingly high concentrations of other ligands were required to displace the binding. In addition, the induction of a prolactin-secreting hard tumor in rats by subcutaneous inoculation of the 235-1 cells failed to induce measurable dopamine receptors associated with the tumor cells. In order to address the possibility that there were functional dopamine receptors on these cells, but that they could not be resolved with either the cell column and cyclic AMP studies or the radioreceptor assay, the clone cells were incubated with 0.1-100 nM bromocriptine for up to 8 days. Bromocriptine had no effect on the growth rate or prolactin secretion of the 235-1 clone but inhibited prolactin release from anterior pituitary cells by over 73% in control studies. We conclude that the 235-1 clone does not express dopamine receptors and that the presence of dopamine receptors is obligatory for the typical inhibitory effects of bromocriptine on prolactin release and pituitary cell growth.

Animals↗
PubMed1984

Prolactin desensitizes the prostaglandin E1-dependent adenylyl cyclase in the rat prostate gland.

Prior exposure of the rat ventral prostate to a high dose of ovine prolactin in vivo or in vitro caused the specific desensitization of the prostaglandin E1-dependent adenylyl cyclase. Maximal desensitization was achieved in vivo 6 h after exposure to 100 micrograms prolactin and complete resensitization occurred after 7 days. No heterologous desensitization of the response of the cyclase to other hormones tested was observed. Incubation of isolated secretory cells with prolactin and prostaglandin E1 desensitized the subsequent response to the same prostaglandin. Simultaneous exposure of the cells to indomethacin prevented the prolactin-induced effect. Prolactin could also induce similar changes in the prostaglandin E1-dependent cyclase of rat Leydig cell tumour cells in vivo, suggesting that this may represent a phenomenon shared by other prolactin target organs. This study supports the hypothesis that prostaglandins may constitute second messengers for prolactin effects on the prostate gland.

Adenylyl Cyclases↗
PubMed1986

Dopamine and somatostatin inhibit forskolin-stimulated prolactin and growth hormone secretion but not stimulated cyclic AMP levels in sheep anterior pituitary cell cultures.

Forskolin, an activator of adenylate cyclase, has been used to investigate the effects of raising pituitary cell cyclic AMP concentrations on prolactin and growth hormone secretion and to examine the role of cyclic AMP in the inhibitory actions of dopamine and somatostatin. Incubation of cultured ovine pituitary cells with forskolin (0.1-10 microM; 30 min) produced a modest dose-related increase in prolactin release (120-140% of basal) but a much greater stimulation of growth hormone secretion (170-420% of basal). Cellular cyclic AMP concentrations were only increased in the presence of 1 and 10 microM forskolin (2-5.5 times basal). A study of the time course for forskolin (10 microM) action showed that stimulation of prolactin (1.5-fold) and growth hormone (4.7-fold) secretion occurred over 15 min; subsequently (15-60 min) the rate of prolactin secretion from forskolin-treated cells was equivalent to that measured in controls, while growth hormone release remained elevated. Cellular cyclic AMP concentrations were also rapidly stimulated by forskolin (10 microM); they reached a maximum (12 times control) within 15 min, and then declined (15-60 min) but remained elevated relative to those in untreated cells (4.9 times control at 60 min). Dopamine (0.1 microM) inhibited basal secretion of both prolactin and growth hormone. In the presence of forskolin (0.1-10 microM), dopamine (0.1 microM) inhibited prolactin secretion to below the basal level and considerably attenuated the stimulation of growth hormone secretion. Similarly, somatostatin suppressed both basal and forskolin-induced prolactin and growth hormone secretion. However, neither dopamine nor somatostatin significantly decreased the stimulatory effect of forskolin on cellular cyclic AMP accumulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1990

Prolactin stimulates transcription of growth-related genes in Nb2 T lymphoma cells.

The pituitary peptide hormone prolactin exerts a profound effect on various physiological processes involving both cellular proliferation and differentiation. The rat Nb2 T lymphoma cell line has been used as a model system for studying prolactin regulation of cell proliferation. Several genes associated with cell growth (c-myc, ornithine decarboxylase (ODC), heat shock protein 70 (hsp 70)-homologue, and beta-actin) are induced rapidly within 4 h after prolactin addition. Nuclear run-on transcription assays indicate that prolactin induction of these growth-related genes occurs primarily at the transcriptional level. According to the different kinetics of transcriptional response to prolactin, these growth-related genes can be divided into immediate-early (actin, c-myc), early (ODC) and mid-G1 (hsp 70-homologue) genes. Thus, prolactin may regulate Nb2 T cell-proliferative responses by modulating the transcriptional induction of various growth-related genes. These studies also represent a first report of a transcriptional cascade set off in rapid response to prolactin in cultured T cells.

Actins↗
PubMed1993

Effect of various protein kinase inhibitors on the induction of milk protein gene expression by prolactin.

Prolactin has many known functions and one of them is to induce the expression of milk protein gene expression in the mammary gland. Specific membrane receptors have been recently characterized but the transduction mechanism involved in the transfer of the prolactin signal to milk protein genes remains unknown. In the present work, it is shown that several protein kinase inhibitors block prolactin action on milk protein genes. Primary rabbit mammary cells were cultured for several days on floating collagen gel in a serum-free medium. Prolactin and the inhibitors of protein kinase were then added to the culture medium. After 1 day, the concentration of alpha s1-casein in the culture medium was measured using a specific radioimmunoassay. The concentration of several mRNAs in cell extracts was also evaluated using Northern blot analysis. alpha s1-Casein secretion and alpha s1-casein mRNA accumulation were induced by prolactin. This induction was blocked by staurosporine, sphingosine, quercetin, genistein and to some extent by o-hydroxyphenyl acetate, but not by H7, polymyxin B, benzylsuccinate and lavendustin A. The concentration of the mRNA coding for transferrin, which is abundantly secreted in rabbit milk independently of prolactin action, was only moderately altered by the inhibitors. The concentration of two house-keeping mRNAs, beta-actin and glyceraldehyde 3-phosphate dehydrogenase, was lowered only by genistein after 1 day but not after 4 h of culture. These data show for the first time that a Ser/Thre kinase, which is not kinase C, and possibly a tyrosine kinase is involved in the transduction of the prolactin message from the receptor to the milk protein genes.

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine↗
PubMed1996

Cloning, sequencing and functional analysis of a truncated cDNA encoding red deer prolactin receptor: an alternative tyrosine residue mediates beta-casein promoter activation.

This study reports the isolation and in vitro characterisation of a truncated cDNA encoding the red deer long form prolactin receptor. The cDNA sequence predicts a protein of 557 amino acids which differs from the rat sequence by a 3' truncation of the cytoplasmic domain located 34 residues before the stop codon. The deer sequence shares the regions of homology which are important for maintenance of structural and functional integrity, high affinity binding and signal transduction. However, the truncated deer receptor lacks the most C-terminal tyrosine residue in the intracellular domain which is believed to be essential for activation of the beta-casein promoter. Transfection studies of the cervine cDNA into human 293 fibroblast cells confirmed the expression of a receptor that has high affinity binding to ovine prolactin (Ka = 0.65 x 10(9)M(-1) and Bmax = 548.6 fmol/mg protein). Co-transfection of CHO cells with expression vector encoding the cervine prolactin receptor cDNA along with a fusion gene containing the promoter region of beta-casein followed by beta-luciferase coding sequence led to 8.13 +/- 0.13-fold induction of luciferase enzyme activity in the presence of 400 ng/ml ovine prolactin. This was comparable to fold induction observed with the wild type long form rat prolactin receptor (6.37 +/- 0.48); macaque growth hormone receptor was without effect. Western blot analysis demonstrated tyrosine phosphorylation of the cervine receptor and the associated kinase Jak2 following stimulation with prolactin. This confirms that the cervine cDNA although truncated is fully functional and that Jak2 and an alternative tyrosine residue in the intracellular domain are involved in the signalling pathway leading to activation of the beta-casein promoter. Northern blot analysis provides evidence that the prolactin receptor in the liver is encoded by transcripts of approximately 2.5 and 3.5 kb. Comparison of Northern blots of different deer species suggests that the receptor is conserved amongst the Cervidae. Northern blot analysis of red deer testis suggests that this species expresses a second form of the receptor, encoded by a transcript of 1.7 kb, which may correspond to a smaller receptor form or a binding protein.

Amino Acid Sequence↗
PubMed1993

Acute or chronic administration of prolactin alters ovine infections of Haemonchus contortus.

Prolactin has been implicated as a modulator in the phenomenon of periparturient egg rise during ovine nematodiasis. In the first experiment, lambs (4 months of age) with patent infections (10,000 infective larvae) of Haemonchus contortus were injected daily (Days 28-39 post-inoculation (PI)) with prolactin (20 or 200 IU) or saline. Fecal egg concentrations and total daily egg production were monitored for each lamb. After 12 days, lambs injected with the lower dose of prolactin had the highest daily egg production. Fewer adult worms were collected from prolactin-treated lambs, and the female worms were larger than those from the saline-injected controls. Worm size and number were not correlated. In the second experiment, lambs were injected daily with ovine prolactin (25 IU) or saline. Five days after initiation of treatments, each lamb was inoculated with 3000 infective larvae of H. contortus. After 42 days of injections (Day 37 PI), prolactin-treated lambs had larger and fewer worms, with higher fecundity, than saline-treated controls. Increases in endogenous circulating prolactin during late pregnancy and lactation in ewes, therefore, might contribute to periparturient egg rise irrespective of the developmental stage of the parasite when the hormone exposure occurs.

Animals↗
PubMed1976

Comparison of secreted and extracted forms of rat pituitary prolactin.

Prolactin secreted by rat anterior pituitary explants into organ culture medium was purified by salt fractionation and gel filtration. A yield of 22 mg/g was obtained, which clearly represented de novo synthesis and secretion of the hormone. Comparative characterization studies were performed on the secreted prolactin and pituitary extracted rat prolactin obtained from the National Institute of Arthritis, Metabolism and Digestive Disease. The biological and immunological activity estimates of both forms were comparable, although the specific activities of the secreted prolactin were somewhat lower than those of the pituitary prolactin. The secreted and extracted forms of prolactin appeared to be identical in primary structure as evidenced by similar amino acid compositions and identical NH2-terminal sequences. Circular dichroism spectra suggested that there may be differences in tertiary structure, since the positive tryptophan band at 292 nm, which eas observed with extracted hormone, was absent in the secreted prolactin.

Amino Acids↗
PubMed1976

Phospholipases and the effect of prolactin on uridine incorporation into RNA in mammary gland explants of mice.

The possible effects of phospholipase A and phospholipase C on the rate of uridine incorporation into RNA in mammary gland explants of mice were tested. Phospholipase C had no effect on the rate of uridine incorporation, but it did suppress the action of prolactin on this metabolic parameter. In contrast, phospholipase A was found to stimulate the rate of uridine incorporation into RNA in a manner similar to that of prolactin. The time-courses for the onset of the prolactin and phospholipase A effects were the same. Also, the phospholipase A effect was nonadditive to the effect produced by a maximally stimulatory concentration of prolactin. Finally it was observed that, like the prolactin effect, the phospholipase A effect was abolished by incubation with dibutyryl cyclic AMP, theophylline, quinine, indomethacin and prostaglandin E1. Further, the phospholipase A effect was nonadditive to the prolactin-like effects produced by the cyclic GMP, prostaglandin F2alpha or arachidonic acid. These data therefore suggest that prolactin and phospholipase A stimulate RNA synthesis in mammary gland explants via similar processes.

Animals↗
PubMed1984

Neurotransmitter effects on in vitro prolactin and growth hormone release from fowl pituitary glands: dopamine and noradrenaline.

Pituitary glands and hypothalami from broiler fowl heads were incubated alone or together with dopamine, noradrenaline or monoaminergic drugs (apomorphine, pimozide, phentolamine, isoproterenol and propranolol). The basal release of both prolactin and growth hormone was not affected by any of these amines or aminergic drugs. The co-incubation of pituitary glands with whole hypothalami consistently stimulated prolactin and growth hormone secretion. Apomorphine inhibited hypothalamus-induced prolactin and growth hormone release and the response was blocked by pimozide. Noradrenaline markedly stimulated hypothalamus-induced prolactin release, an effect antagonised by phentolamine. Thyrotrophin-releasing hormone (TRH) stimulated the release of prolactin and this stimulation was reversed, in a dose-related manner, by dopamine. TRH also increased the release of growth hormone, in the presence or absence of dopamine. These results demonstrate inhibitory dopaminergic effects on prolactin and growth hormone secretion and stimulatory noradrenergic effects on prolactin release. These aminergic effects may be mediated at pituitary and/or hypothalamic sites.

Animals↗
PubMed1985

Effects of putative neurotransmitters on release of prolactin from pituitary glands of the domestic fowl co-incubated with hypothalamic tissue.

Pituitary glands and hypothalami from broiler fowl heads were incubated alone or together with histamine, gamma-aminobutyric acid (GABA) or acetylcholine (ACh) as well as with catecholamines or neurotransmitter antagonists. Histamine and ACh stimulated, whereas GABA inhibited, the hypothalamus-induced release of prolactin, responses blocked by their specific antagonists. The dopamine antagonist pimozide, but not adrenergic (both alpha and beta), serotoninergic or cholinergic antagonists, prevented the actions of histamine and GABA. None of the antagonists except the cholinergic blocker, atropine, affected ACh-induced release of prolactin. Neither histamine nor ACh prevented inhibition of prolactin release by dopamine or stimulation of prolactin release by noradrenaline. GABA did not affect the response to noradrenaline. Furthermore, histamine, GABA and ACh had no effects on thyrotrophin releasing hormone-stimulated release of prolactin directly at the pituitary level. These results suggest that histamine and GABA affect prolactin release from chicken pituitaries in vivo by modifying the activity of the dopaminergic system. Acetylcholine may stimulate the secretion of prolactin releasing factor from the hypothalamus.

Acetylcholine↗
PubMed1979

Cellular basis of prolactin action: involvement of cyclic nucleotides, polyamines, prostaglandins, steroids, thyroid hormones, Na/K ATPases and calcium: relevance to breast cancer and the menstrual cycle.

The mechanisms of prolactin action are uncertain. Prolactin effects are characterised by great variability in the prolactin concentration required to produce a response and by the frequent occurrence of "bell-shaped" dose response curves. Relationships between prolactin and thyroid hormones and steroids are difficult to understand: both steroids and thyroid hormones may potentiate or inhibit prolactin effects in different situations. At the second messenger level, claims have been made that cyclic nucleotides, polyamines, Na/K ATPases and prostaglandins are involved. There is evidence that prostaglandin E1 may be an important second messenger and it is proposed that this is the clue to understanding the complexity. At low concentrations PGE1 enhances intracellular calcium release and at high concentrations PGE1 inhibits calcium release. The other second messengers proposed are all probably dependent upon calcium. Many prolactin effects may involve both PGE1 and another second messenger: at low prolactin concentrations PGE1 will potentiate the other messenger whereas at high concentrations the PGE1 effect will be inhibitory leading to a bell-shaped response. Thryoid hormones seem to enhance while glucocorticoids inhibit PGE1 synthesis. PGE1 dependent effects will thus be enhanced by thyroid hormone and blocked by cortisol. The reverse will be true of effects dependent on other second messengers.

Breast Neoplasms↗
PubMed1991

External irradiation of growth hormone producing pituitary adenomas: prolactin as a marker of hypothalamic and pituitary effects.

Fifty-six patients with acromegaly were treated with external irradiation, 50 Gy, after unsuccessful pituitary surgery. A 50% reduction of pre-irradiation growth hormone levels was obtained in 51/56 patients. This level was reached after 26 +/- 14 months in 33 patients with prolactin levels less than 25 micrograms/l at diagnosis, after 21 +/- 17 months in 18 patients with prolactin greater than or equal to 25 micrograms/l, and after 20 +/- 21 months in 12 patients with prolactin greater than 40 micrograms/l at diagnosis. A further 50% decrease of growth hormone levels was obtained in 40/51 patients 42 +/- 22 months after radiotherapy, indicating that in clearly responsive patients, the growth hormone depression after radiotherapy follows a first order reaction. Four patients did not reach a 50% reduction of growth hormone levels 48-80 months after radiotherapy. During 10 years of follow-up, the growth hormone depression tended to be more pronounced in patients with mixed secretion of growth hormone and prolactin. The reduction of growth hormone levels was not correlated with the irradiated volume or the cumulative radiation effect. Within the first year, prolactin increased within the normal range in normoprolactinemic patients and remained so during follow-up. In hyperprolactinemic patients, prolactin decreased successively but to a lesser extent than growth hormone. Pituitary insufficiencies increased over time and three patients developed GH-insufficiency. Hypothalamic damage as indicated by prolactin changes was a regular phenomenon after radiotherapy.

Acromegaly↗
PubMed1996

Role of dopamine in the inhibitory control of growth hormone and prolactin release by gastrin-releasing peptide.

The ability of gastrin-releasing peptide to inhibit the release of growth hormone and prolactin by a hypothalamic mechanism has been previously reported. To determine whether or not these effects involved the hypothalamic dopaminergic neurons, ovariectomized female rats were pretreated with the dopamine receptor blocker, pimozide (0.6 mg/kg, SC), or the diluent 35 min prior to administration of gastrin-releasing peptide (2 micrograms in 2 microliters 0.9% NaCl) into the third ventricle. The elevation in plasma growth hormone in response to growth hormone-releasing factor (GRF; 1 microgram/kg, i.v.) was blocked by gastrin-releasing peptide as previously reported following pretreatment with the diluent, but occurred following the injection of pimozide, reversing the inhibitory action of gastrin-releasing peptide. Some control animals that were injected with the pimozide vehicle exhibited elevated plasma prolactin levels compared to levels in uninjected controls. Gastrin-releasing peptide significantly lowered plasma prolactin concentrations in this group of animals. As expected, plasma prolactin levels were elevated following pimozide treatment due to the removal of inhibitory dopaminergic control. Prolactin concentrations were unresponsive to gastrin-releasing peptide treatment in this paradigm and remained elevated throughout the 40-min duration of sampling. We interpret these data to indicate that gastrin-releasing peptide exerts its inhibitory actions on the release of growth hormone and prolactin through a dopaminergic mechanism. Gastrin-releasing peptide may elicit the release of dopamine from tuberoinfundibular neurons, which a) stimulates release of somatostatin, thus inhibiting the release of growth hormone, and b) reaches the pituitary directly via the hypophysial portal vessels to inhibit the release of prolactin from the lactotropes.

Animals↗
PubMed1991

Daily rhythm of prolactin and corticosterone in unrestrained, incubating turkey hens.

Plasma concentrations of prolactin and corticosterone were determined in hourly samples collected over a 25-hr period from unrestrained turkey hens exhibiting incubation (broody) behavior. Hens were maintained in cages on a 14 hr light: 10 hr dark photoperiod. Mean plasma prolactin concentration increased significantly late in the dark period to reach maximum daily levels of 496 ng/ml at the start of the photophase. However, a well-defined daily rhythm in prolactin secretion was not evident. Plasma corticosterone concentration showed a significant daily rhythm characterized by a major secretory peak (7.14 ng/ml) in the middle of the light period and a smaller, less well-defined peak (4.11 ng/ml) during the dark period. Both prolactin and corticosterone secretion ranged widely throughout the day in individual hens in a manner suggestive of pulsatile hormone secretion. This study demonstrates that the extremely high prolactin concentrations characteristic of the incubating turkey hen reflect large, dynamic changes in plasma prolactin concentrations occurring throughout the photoperiod, rather than a constantly high level of prolactin secretion.

Animals↗
PubMedDate not supplied

The effect of ethanol on prolactin release from pituitary cells in vitro.

Exposure to ethanol is recognized to cause reproductive impairment in man and animals. Since elevated levels of prolactin will interfere with normal functioning of the hypothalamic-pituitary-gonadal axis, and since ethanol has been shown by others to lead to increased prolactin secretion in vivo, the present in vitro study was undertaken to determine whether there is a direct effect of ethanol (ETOH) on prolactin release. Prolactin release from anterior pituitary cells maintained in monolayer culture and exposed to either no ethanol or media containing ethanol at concentrations of 50, 100, 200, or 400 mg% was measured at 1, 4, 24, 48, 72 hours in incubation. Ethanol added directly to pituitary cells stimulated prolactin release at all time points examined. Significant stimulation occurred with addition of low and mid-range ethanol concentrations (50-200 mg%); no augmented prolactin secretory response was seen with the highest ethanol concentration used (400 mg%). This pattern of response was maintained throughout the entire 72 hour incubation period. Thus, the effect of ethanol on prolactin secretion is mediated, at least in part, at the anterior pituitary level.

Animals↗
PubMed1994

The effect of prolactin, human chorionic gonadotropin, insulin and insulin-like growth factor 1 on adrenal steroidogenesis in isolated guinea-pig adrenal cells.

The controlling mechanism for adrenal androgen production has not been elucidated. The presence of receptors for prolactin, human chorionic gonadotropin (hCG), insulin and insulin-like growth factor 1 (IGF-1) in the adrenal cortex raises the possibility of their involvement in the control of adrenal steroidogenesis. This study was undertaken to investigate the effects of prolactin, hCG, insulin and IGF-1 in the presence and absence of ACTH on cortisol and androgen production using isolated guinea-pig adrenal cells. hCG 10(-7) and 10(-6) M significantly increased cortisol (P < 0.05) production. hCG 10(-6) M significantly increased androstenedione (A4) (P < 0.05) production. In the presence of ACTH, 10(-12) M, hCG 10(-6) M significantly increased the cortisol (P < 0.01) and A4 (P < 0.01) responses. Although the mean cortisol and A4 response to ACTH 10(-9) M was reduced in the presence of hCG 10(-6) M, this was not statistically significant. Prolactin 10(-8) M increased cortisol (P < 0.01), A4, and dehydroepiandrosterone (P < 0.05) production. In the presence of ACTH 10(-12) M, prolactin 10(-8) M increased the cortisol and A4 (P < 0.05) responses. However, the maximally ACTH-stimulated cortisol and A4 responses were not significantly altered in the presence of prolactin 10(-8) M. Insulin 10(-11)-10(-8) M and IGF-1 10(-10)-10(-7) M resulted in no significant increase in cortisol, A4 or dehydroepiandrosterone production. This study suggests that prolactin and hCG could play a role in modulation of adrenal steroidogenesis, particularly when ACTH levels are low. However, there was no evidence that prolactin or hCG is the specific cortical androgen stimulating hormone.

Adrenal Glands↗
PubMed1992

The effects of a dopamine antagonist on luteinizing hormone and prolactin release in women with anorexia nervosa and in normal controls.

To evaluate the possible role of central dopaminergic suppression of gonadotropin secretion in the genesis of amenorrhea associated with anorexia nervosa (A.N.), a central D-2 dopamine receptor blocker was administered to 10 women with A.N. and 10 regularly menstruating age-matched controls. Serum prolactin and luteinizing hormone (LH) levels were measured at -15, 0, 30, 60, 120, and 180 min after administration of metoclopramide (10 mg orally). Mean basal prolactin (p less than 0.001) and estradiol levels (p less than 0.02) were significantly lower in women with A.N. The prolactin response to metoclopramide was significantly impaired in women with anorexia nervosa. No correlation was found between the prolactin response and percentage ideal body weight. Basal and post-stimulation prolactin levels were correlated with estradiol levels. After adjusting for the effects of estradiol, significant differences between patients with A.N. and controls remained in prolactin levels at baseline (p less than 0.01), 120 min (p less than 0.02) and 180 min (p less than 0.05). Metoclopramide did not induce a significant rise in LH levels in either the A.N. or control groups. These data are consistent with central dopaminergic inhibition of prolactin secretion in anorexia nervosa but do not support the hypothesis that central dopaminergic inhibition is related to diminished LH release in this state.

Adolescent↗